← Back to Search

Checkpoint Inhibitor

Arm A for Non-Small Cell Lung Cancer (RELATIVITY1093 Trial)

Phase 3
Waitlist Available
Research Sponsored by Bristol-Myers Squibb
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
* Participants must have histologically confirmed Stage IV or recurrent Non-small Cell Lung Cancer (NSCLC) of non-squamous (NSQ) histology with tumor cell PD-L1 expression 1% to 49% as determined by a central laboratory
* Participants must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 criteria.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2.5 years
Awards & highlights

Summary

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 1-49%

Who is the study for?
This trial is for adults with stage IV or recurrent non-squamous non-small cell lung cancer showing PD-L1 levels between 1-49%. Participants should not have had prior systemic treatment for their advanced disease.
What is being tested?
The study aims to compare the effectiveness of two treatments: Nivolumab and Relatlimab combined with chemotherapy versus Pembrolizumab with chemotherapy, in patients matching the specific cancer criteria.
What are the potential side effects?
Potential side effects may include immune-related reactions, fatigue, nausea, skin issues, and changes in blood tests. The severity can vary from mild to serious requiring medical attention.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2.5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2.5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Overall survival (OS)
Secondary study objectives
Duration of response (DoR)
Number of participants with adverse events (AEs)
Number of participants with immune-mediated adverse events (IMAEs)
+4 more

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Arm AExperimental Treatment5 Interventions
Group II: Arm BActive Control4 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cisplatin
2013
Completed Phase 3
~1940
Pemetrexed
2014
Completed Phase 3
~5250
Nivolumab
2014
Completed Phase 3
~4740
Carboplatin
2014
Completed Phase 3
~6670
Relatlimab
2018
Completed Phase 2
~1120

Find a Location

Who is running the clinical trial?

Bristol-Myers SquibbLead Sponsor
2,666 Previous Clinical Trials
4,132,327 Total Patients Enrolled
~533 spots leftby Jul 2030
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top